ARTICLE | Finance
With €27M at launch, Vico revives Prosensa oligonucleotide programs, aims to edit RNA for Rett
July 29, 2020 9:22 AM UTC
With two RNA manipulation platforms united under one roof, Dutch biotech Vico will deploy its new series A round for clinical development of a program founder and Chairman Luc Dochez knows well from his time at Prosensa.
Vico Therapeutics B.V. said Wednesday it had raised €27 million ($31.6 million) in a series A round led by LSP. Joining that firm were co-leader Kurma Partners as well as Pontifax, Droia Genetic Disease, Polaris Partners and Pureos Bioventures...